Please login to the form below

Not currently logged in
Email:
Password:

Signifor

This page shows the latest Signifor news and features for those working in and with pharma, biotech and healthcare.

Novartis' acromegaly therapy cleared by FDA

Novartis' acromegaly therapy cleared by FDA

Novartis' acromegaly therapy cleared by FDA. Signifor LAR shows superior efficiency to older treatments. ... Signifor LAR needs to be given just once a month, allowing it to compete head-to-head with its rivals in this setting.

Latest news

  • Novartis gets EU nod for rare disease drug Signifor Novartis gets EU nod for rare disease drug Signifor

    Novartis gets EU nod for rare disease drug Signifor. Long-acting formulation of drug approved for growth disorder acromegaly. ... This first approval of Signifor in acromegaly marks a much needed advance in the treatment of this rare disease.".

  • Novartis plans filings for acromegaly candidate Novartis plans filings for acromegaly candidate

    A phase III trial of Novartis' somatostatin analogue Signifor has suggested it could be effective for the growth hormone disorder acromegaly. ... The shorter-acting, subcutaneous form of Signifor was approved in 2012, and to date Novartis has not broken

  • Novartis cancer chief Hoppenot leaves for top job at Incyte Novartis cancer chief Hoppenot leaves for top job at Incyte

    During his time at the helm of Novartis' cancer division Hoppenot presided over the launch of two new cancer therapies, Jakavi for myelofibrosis in 2011 and Signifor (pasireotide) for Cushing's

  • Year-end FDA approvals for Novartis, GSK drugs Year-end FDA approvals for Novartis, GSK drugs

    Year-end FDA approvals for Novartis, GSK drugs. Agency gives go-ahead to Cushing’ s disease treatment Signifor and raxibacumab for inhalational anthrax. ... In addition to Cushing's syndrome, Signifor is also being developed to treat the rare endocrine

  • Novartis' heart failure drug serelaxin meets targets Novartis' heart failure drug serelaxin meets targets

    Novartis' heart failure drug serelaxin meets targets. And FDA committee backs Signifor for Cushing's disease. ... If the FDA concurs with that view, somatostatin analogue Signifor could become the first approved treatment for Cushing's in the US.

More from news
Approximately 5 fully matching, plus 4 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics